{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:46:29Z","timestamp":1792586789003,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"C\u00e1tedra Astrazeneca (EffiHealth), Universitat de Lleida"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40258-026-01065-z","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T15:15:22Z","timestamp":1788707722000},"page":"987-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pricing Combination Therapies: A Systematic Review of Value Attribution, Cost-Sharing Mechanisms and Policy Frameworks"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-1776","authenticated-orcid":false,"given":"Marta","family":"Trapero-Bertran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-6768","authenticated-orcid":false,"given":"Carlos","family":"Martin-Saborido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-1321","authenticated-orcid":false,"given":"Jorge","family":"Mestre-Ferrandiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-7225","authenticated-orcid":false,"given":"Nuria","family":"Amarilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Seg\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"issue":"Suppl 2","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4269\/ajtmh.2004.71.196","volume":"71","author":"PG Coleman","year":"2004","unstructured":"Coleman PG, Morel C, Shillcutt S, Goodman C, Mills AJ. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa. Am J Trop Med Hyg. 2004;71(Suppl 2):196\u2013204.","journal-title":"Am J Trop Med Hyg"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"20141356","DOI":"10.1098\/rsif.2014.1356","volume":"12","author":"EY Klein","year":"2015","unstructured":"Klein EY, Smith DL, Cohen JM, Laxminarayan R. Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis. J R Soc Interface. 2015;12:20141356. https:\/\/doi.org\/10.1098\/rsif.2014.1356.","journal-title":"J R Soc Interface"},{"issue":"1","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jval.2024.08.012","volume":"28","author":"AH Briggs","year":"2025","unstructured":"Briggs AH, Doyle-Connolly A, Schneider J, Podkonjak T, Taylor H, Roffe E, et al. An attribution of value framework for combination treatments. Value Health. 2025;28(1):72\u201380.","journal-title":"Value Health"},{"issue":"1","key":"1065_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jval.2024.07.019","volume":"28","author":"L Steuten","year":"2025","unstructured":"Steuten L, Lothgren M, Bruce A, Campioni M, Towse A. Proposal for a general outcome-based value attribution framework for combination therapies. Value Health. 2025;28(1):81\u20137.","journal-title":"Value Health"},{"key":"1065_CR5","volume-title":"Access to oncology combination therapies in Europe: today\u2019s challenges and solutions","author":"EFPIA","year":"2023","unstructured":"EFPIA. Access to oncology combination therapies in Europe: today\u2019s challenges and solutions. Brussels: EFPIA; 2023."},{"issue":"1","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jval.2024.11.002","volume":"28","author":"O Ciani","year":"2025","unstructured":"Ciani O, Jommi C. Value attribution for combination treatments: two potential solutions for an insoluble problem. Value Health. 2025;28(1):70\u20131.","journal-title":"Value Health"},{"issue":"2","key":"1065_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020270","volume":"10","author":"MC Michel","year":"2022","unstructured":"Michel MC, Staskin D. Study designs for evaluation of combination treatment: focus on individual patient benefit. Biomedicines. 2022;10(2):270. https:\/\/doi.org\/10.3390\/biomedicines10020270.","journal-title":"Biomedicines"},{"key":"1065_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10198-002-0111-z","volume":"3","author":"B Detournay","year":"2002","unstructured":"Detournay B, Pribil C, Lourdanne E, Price M. Budget impact model for determining the costs of introducing inhaled salmeterol\/fluticasone propionate combination for the management of persistent asthma in France. Eur J Health Econ. 2002;3:149\u201355. https:\/\/doi.org\/10.1007\/s10198-002-0111-z.","journal-title":"Eur J Health Econ"},{"key":"1065_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40258-023-00795-8","volume":"21","author":"CH Henshall","year":"2023","unstructured":"Henshall CH, Dank\u00f3 D, Barham L, Esp\u00edn J, Felix J, Harney M, et al. Review and assessment of policy options for improving access to combination therapies in oncology in Europe. Appl Health Econ Health Policy. 2023;21:537\u201346. https:\/\/doi.org\/10.1007\/s40258-023-00795-8.","journal-title":"Appl Health Econ Health Policy"},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","volume":"18","author":"C Campillo-Artero","year":"2020","unstructured":"Campillo-Artero C, Puig-Junoy J, Seg\u00fa-Tolsa JL, Trapero-Bertran M. Price models for multi-indication drugs: a systematic review. Appl Health Econ Health Policy. 2020;18:47\u201356. https:\/\/doi.org\/10.1007\/s40258-019-00517-z.","journal-title":"Appl Health Econ Health Policy"},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10198-021-01427-5","volume":"23","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Value drivers of development stage biopharma companies. Eur J Health Econ. 2022;23:1287\u201396. https:\/\/doi.org\/10.1007\/s10198-021-01427-5.","journal-title":"Eur J Health Econ"},{"key":"1065_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1065_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2025.102976","volume":"101","author":"KR Brekke","year":"2025","unstructured":"Brekke KR, Dalen DM, Straume OR. Taking the competitor\u2019s pill: when combination therapies enter pharmaceutical markets. J Health Econ. 2025;101:102976. https:\/\/doi.org\/10.1016\/j.jhealeco.2025.102976.","journal-title":"J Health Econ"},{"issue":"4","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10198-025-01773-8","volume":"26","author":"A Towse","year":"2025","unstructured":"Towse A, Briggs A, Steuten L. Pricing combination products: not how but who? Eur J Health Econ. 2025;26(4):537\u201340. https:\/\/doi.org\/10.1007\/s10198-025-01773-8.","journal-title":"Eur J Health Econ"},{"key":"1065_CR15","unstructured":"Bundesverfassungsgericht. Unsuccessful constitutional complaints against price control measures in legislation concerning statutory health insurance. Press release No. 61\/2025; 16 July 2025. https:\/\/www.bundesverfassungsgericht.de\/SharedDocs\/Pressemitteilungen\/EN\/2025\/bvg25-061.html. Accessed on 10 Jan 2026."},{"issue":"11","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1287\/mnsc.2022.01721","volume":"70","author":"E Adida","year":"2024","unstructured":"Adida E. Indication-based pricing for multi-indication drugs. Manag Sci. 2024;70(11):7506\u201323.","journal-title":"Manag Sci"},{"key":"1065_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199253","volume":"14","author":"I Maes","year":"2023","unstructured":"Maes I, Kok E, De Torck PJ, Mestre-Ferrandiz J, Simoens S. Not one, but many: developing a multi-indication pricing model for medicines in Belgium. Front Pharmacol. 2023;14:1199253.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1065_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","volume":"20","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Mills M, Kanavos P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022;20(5):757\u201368. https:\/\/doi.org\/10.1007\/s40258-022-00737-w.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1065_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp13010002","volume":"13","author":"H Armstrong","year":"2025","unstructured":"Armstrong H, Petrova A, Wilsdon T, Homoki H, Roediger A. Multi-year multi-indication agreements for supporting patient access to oncology medicines with multiple indications: an experimental approach or here to stay? J Mark Access Health Policy. 2025;13(1):2. https:\/\/doi.org\/10.3390\/jmahp13010002.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"1065_CR20","doi-asserted-by":"publisher","first-page":"1964791","DOI":"10.1080\/20016689.2021.1964791","volume":"9","author":"R Lawlor","year":"2021","unstructured":"Lawlor R, Wilsdon T, Darquennes E, Hemelsoet D, Huismans J, Normand R, et al. Accelerating patient access to oncology medicines with multiple indications in Europe. J Mark Access Health Policy. 2021;9(1):1964791. https:\/\/doi.org\/10.1080\/20016689.2021.1964791.","journal-title":"J Mark Access Health Policy."},{"issue":"10","key":"1065_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.18553\/jmcp.2019.25.10.1082","volume":"25","author":"LP Garrison Jr","year":"2019","unstructured":"Garrison LP Jr, Towse A. A strategy to support efficient development and use of innovations in personalized medicine and precision medicine. J Manag Care Spec Pharm. 2019;25(10):1082\u20137. https:\/\/doi.org\/10.18553\/jmcp.2019.25.10.1082.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01065-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:23:25Z","timestamp":1792585405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01065-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01065-z","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jorge Mestre-Ferrandiz is an editorial board member of Applied Health Economics and Health Policy. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marta Trapero-Bertran conceived the study and led the overall design. Marta Trapero-Bertran, Carlos Martin-Saborido, Jorge Mestre-Ferrandiz, and Llu\u00eds Seg\u00fa contributed to the development of the search strategy, study selection, and methodological design, including double screening and review of the included studies. Nuria Amarilla contributed specifically to the legal and regulatory analysis, including the identification and interpretation of relevant legal frameworks related to combination therapies. Marta Trapero-Bertran prepared the first draft of the manuscript. All authors, including Llu\u00eds Seg\u00fa, contributed to the conception and design of the study. All authors, except Llu\u00eds Seg\u00fa, contributed to the interpretation of the results and critically revised subsequent versions of the manuscript. All living authors approved the final version of the manuscript. Llu\u00eds Seg\u00fa passed away during the preparation of the results section. His important contribution to the conception, design, and early stages of the study is gratefully acknowledged. Permission to include him as a co-author was obtained from his wife.","order":2,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data supporting the findings of this study consist of the articles included in the systematic review and the structured data extraction performed by the authors. The list of included studies is provided in the supplementary materials. The review protocol was prospectively registered in the Open Science Framework (OSF;\n                      \n                      ). Additional materials, including the data extraction framework, are available from the corresponding author upon reasonable request. No primary individual-level data were collected.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":6,"name":"Ethics","label":"Consent for publication (from patients\/participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}